Peter A. Ward (Chair) is Professor and Chairman of the Department of Pathology of the University of Michigan Medical School. Dr. Ward received his MD from the University of Michigan in 1960 and has worked at Scripps, the Armed Forces Institute of Pathology and the University of Connecticut Health Center. He has an extensive background in immunopathology, inflammation, and the biological role of complement and mechanisms of antibody formation. Dr. Ward is also a member of the Institute of Medicine.
Jane Adams is Associate Director for Public Affair at the Juvenile Diabetes Foundation. Ms. Adams received her BA from University of Vermont. She has an extensive background in policy work and biomedical research. Ms. Adams has had type 1 diabetes since the age of 12.
Denise Faustman is Associate Professor of Medicine at Harvard Medical School and Director of Immunology Laboratories, Massachusetts General Hospital. Dr. Faustman received her MD and PhD from Washington University School of Medicine. She has an extensive background in the role of major histocompatibility complex in transplant rejection and role of defective antigen processing in autoimmunity.
Gerald F. Gebhart is Professor and Head of the Department of Pharmacology at the University of Iowa College of Medicine. Dr. Gebhart received his PhD from the University of Iowa. He has an extensive background in pain and pain modulation and mechanisms of visceral pain and visceral hyperalgesia. Dr. Gebhart is also a member of ILAR Council.
James G. Geistfeld is Director of Laboratory Animal Medicine at Taconic Farms and Vice President of Taconic Ventures. Dr. Geistfeld received his DVM from the University of Minnesota School of Veterinary Medicine. He has an extensive background in methods of producing monoclonal antibodies and methods of producing laboratory animals.
John W. Imbaratto is Manager of Cell Culture Manufacturing at Covance Biotechnology Services, Inc. in Research Triangle Park. Mr. Imbaratto received his BS from Kent State University in Ohio. He has worked in Quality Control and manufacturing since graduation, first as Head of Bacterial Fermentation and Toxoid Manufacturing for Lederle Laboratories, then as Manager of cGMP manufacturing of monoclonal antibodies using the mouse ascites method with Charles River Laboratories. Currently, he is with Covance Biotechnology Services as the Manager of Cell Culture Manufacturing providing in-vitro cGMP contract manufacturing services.
Norman C. Peterson is a Research Associate in the Department of Clinical Studies at the University of Pennsylvania. Dr. Peterson received his DVM from the University of Illinois and his PhD from the University of Pennsylvania. His research involves investigations of oncogenic cell-surface receptor interactions and he has an extensive background in methods of producing monoclonal antibodies.
Fred Quimby is Director of the Center for Laboratory Animal Resources at Cornell University, Ithica. Dr. Quimby received his VMD and PhD from the University of Pennsylvania. He has an extensive background in immunology, differentiation antigens on canine lymphoctes, and immunologic abnormalities in autoimmune disease.
Ann Marshak-Rothstein is Professor of Microbiology and Director of Immunology Training Program at Boston University School of Medicine. Dr. Marshak-Rothstein received her PhD from University of Pennsylvania School of Medicine. She has an extensive background in cellular immunology, murine models of autoimmunity, autoantibody-medicated pathogenesis, and regulation of Fas/FasL medicated apoptosis.
Andrew N. Rowan is Senior Vice President for the Humane Society of the United States. Dr. Rowan received his BA and DPhil from Oxford University. His research interests were initially the biochemistry of intermediary metabolism but he early became interested in the appropriate use of animals in research and in human interactions with, and attitudes towards, animals. He has written extensively on a variety of animal welfare issues including the mouse ascites method for producing monoclonal antibodies. He is currently focusing on how one might assess and minimize animal pain and distress in research animals.
Matthew D. Scharff is Professor of Cell Biology at Albert Einstein College of Medicine. Dr. Scharff received his MD from New York University College of Medicine. He has an extensive background in the basis for immunoglobulin variable region somatic hypermutation and isotope switching to discover better methods of producing monoclonal antibodies for treatment and prevention of disease. He is Co-Chair of the Board of Scientific Councilors and a member of the Executive Committee of the National Cancer Institute. Dr. Scharff is also a member of the National Academy of Sciences.
Stuart F. Schlossman is Professor of Medicine at the Harvard Medical School and Chief of the Division of Tumor Immunology at Dana-Farber Cancer Institute. Dr. Schlossman received his MD from New York University Medical School. In his research he has developed many of the monoclonal antibodies which distinguish various classes of human T lymphocytes and identify the human T cell receptors. Dr. Schlossman is a member of the Institute of Medicine and the National Academy of Sciences.